Aquestive Therapeutics is trading 5.88% up in pre-market at $4.50, versus the August 14, 2026 close of $4.25; no new company-specific announcement explaining the gain was identified.
- Investors may be balancing strong second-quarter revenue growth against a wider reported loss and the $11.7 million debt-extinguishment charge.
- Broader sentiment is modestly positive, with Nasdaq futures up 0.52%, but the catalyst remains unclear.